{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:22:08Z","timestamp":1787862128885,"version":"build-2784847793"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.06.014","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:45:32Z","timestamp":1782373532000},"page":"609-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8144-541X","authenticated-orcid":false,"given":"Roberto","family":"Mina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0945-0144","authenticated-orcid":false,"given":"Lorenzo","family":"Cani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peeter","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.clml.2026.06.014_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.06.014_bib0002","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clml.2026.06.014_bib0003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.06.014_bib0004","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.clml.2026.06.014_bib0005","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10297","key":"10.1016\/j.clml.2026.06.014_bib0006","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2026.06.014_bib0007","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.06.014_bib0008","article-title":"Teclistamab plus Daratumumab in relapsed or refractory multiple myeloma","author":"Costa","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.06.014_bib0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.06.014_bib0010","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.06.014_bib0011","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.06.014_bib0012","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.06.014_bib0013","unstructured":"FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma. 2025. Accessed: January 30, 2026. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-belantamab-mafodotin-blmf-relapsed-or-refractory-multiple-myeloma."},{"key":"10.1016\/j.clml.2026.06.014_bib0014","unstructured":"Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed\/refractory multiple myeloma. 2025. Accessed March 28, 2026. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma\/."},{"issue":"10","key":"10.1016\/j.clml.2026.06.014_bib0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody\u2013drug conjugates in human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clml.2026.06.014_bib0016","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.clml.2026.06.014_bib0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.seminhematol.2025.12.004","article-title":"BCMA biology and therapeutic targeting in multiple myeloma: from ligand signaling to antigen escape","volume":"62","author":"Sezer","year":"2025","journal-title":"Semin Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.06.014_bib0018","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1038\/s41467-025-62530-2","article-title":"B cell maturation antigen (BCMA) is dispensable for the survival of long-lived plasma cells","volume":"16","author":"Menzel","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.clml.2026.06.014_bib0019","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2026.06.014_bib0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","article-title":"Corneal epithelial findings in patients with multiple myeloma treated with antibody\u2013drug conjugate Belantamab Mafodotin in the pivotal, randomized, DREAMM-2 study","volume":"9","author":"Farooq","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"22","key":"10.1016\/j.clml.2026.06.014_bib0021","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","article-title":"Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials","volume":"9","author":"Mateos","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.06.014_bib0022","article-title":"Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography","volume":"23","author":"Matsumiya","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"9","key":"10.1016\/j.clml.2026.06.014_bib0023","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.clml.2024.05.002","article-title":"Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians","volume":"24","author":"Lupia","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.clml.2026.06.014_bib0024","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.06.014_bib0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-021-00494-4","article-title":"Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)","volume":"11","author":"Lonial","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.014_bib0026","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/blood-2021-152681","article-title":"Can patient-reported ocular symptoms guide dose modifications in patients with relapsed\/refractory multiple myeloma receiving Belantamab Mafodotin?","volume":"138","author":"Popat","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.06.014_bib0027","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1200\/JCO.2024.42.16_suppl.7530","article-title":"Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire","volume":"42","author":"Terpos","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.06.014_bib0028","article-title":"Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma","author":"Terpos","year":"2025","journal-title":"Blood J"},{"issue":"10","key":"10.1016\/j.clml.2026.06.014_bib0029","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/ajh.70015","article-title":"Practical guidance on clinical management of Belantamab Mafodotin-associated ocular events","volume":"100","author":"Terpos","year":"2025","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.014_bib0030","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood-2024-204055","article-title":"Belantamab Mafodotin plus cyclophosphamide and Dexamethasone for patients with relapsed or refractory multiple Myeloma: interim results from the UK Myeloma Research Alliance promise clinical trial","volume":"144","author":"Popat","year":"2024","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2026.06.014_bib0031","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.014_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-139315","article-title":"Ocular health of patients with relapsed\/refractory multiple myeloma (RRMM): baseline data from the DREAMM-2 trial of Belantamab Mafodotin (Belamaf)","volume":"136","author":"Popat","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.06.014_bib0033","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","article-title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","volume":"26","author":"Hungria","year":"2025","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.014_bib0034","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/blood-2025-2264","article-title":"Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 dreamm-8 study","volume":"146","author":"Trudel","year":"2025","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.06.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7567","article-title":"Design of the phase 3 DREAMM-10 study: belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM)","volume":"43","author":"Lonial","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.06.014_bib0036","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.06.014_bib0037","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2026.06.014_bib0038","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.06.014_bib0039","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, Lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2026.06.014_bib0040","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.06.014_bib0041","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.clml.2026.06.014_bib0042","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.06.014_bib0043","unstructured":"Gonz\u00e1lez-Calle V. Belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant eligible multiple myeloma patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial. Oral abstract #64. Presented at: 21st International Myeloma Society Annual Meeting; 2024; Rio de Janeiro, BR."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.06.014_bib0044","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-198669","article-title":"Phase I study of Belantamab Mafodotin in combination with standard of care in transplant-ineligible newly diagnosed multiple myeloma: dreamm-9 updated interim analysis","volume":"144","author":"Usmani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.06.014_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(25)04009-1","article-title":"Maintenance therapy with Belantamab, Pomalidomide and Dexamethasone in high-risk myeloma patients: a phase 2 study with a safety run-in - interim analysis","volume":"25","author":"Nooka","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2026.06.014_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2026.03.003","article-title":"The evolution of CAR T-cell, bispecific antibodies and antibody drug conjugates for the treatment of multiple myeloma","author":"Cani","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.06.014_bib0047","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/JCO.2024.42.16_suppl.7543","article-title":"Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Hungria","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.06.014_bib0048","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40487-025-00354-2","article-title":"Practical guidance on the clinical management of ocular adverse events associated with Belantamab Mafodotin for patients with relapsed\/refractory multiple myeloma: Latin American expert panel recommendations","volume":"13","author":"Hungria","year":"2025","journal-title":"Oncol Ther"},{"issue":"1","key":"10.1016\/j.clml.2026.06.014_bib0049","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41408-024-01155-y","article-title":"Results from Arm A of phase 1\/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"14","author":"Popat","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2026.06.014_bib0050","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","article-title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial","volume":"30","author":"Trudel","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.06.014_bib0051","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288203","article-title":"Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma","author":"Musa","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.06.014_bib0052","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz251.039","article-title":"DREAMM 4: a phase I\/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"30","author":"Trudel","year":"2019","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.clml.2026.06.014_bib0053","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2217\/fon-2020-1269","article-title":"Belantamab Mafodotin in combination with novel agents in relapsed\/refractory multiple myeloma: DREAMM-5 study design","volume":"17","author":"Nooka","year":"2021","journal-title":"Future Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.06.014_bib0054","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8073","article-title":"Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14","volume":"40","author":"Hultcrantz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.clml.2026.06.014_bib0055","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1002\/cncr.33809","article-title":"Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study","volume":"127","author":"Lonial","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2026.06.014_bib0056","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025019050","article-title":"Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma","author":"Atrash","year":"2026","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:48:09Z","timestamp":1787860089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2152265026002016"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}